Drugs / Depo-Eligard
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT06282588 Background | Dec 2023 → Jul 2030 expected | prostate cancer | Cancer Research Antwerp | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Depo-Eligard | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06282588 ↗ |
| Route | Subcutaneous | “45 mg, subcutaneous use” NCT06282588 ↗ |